{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:41:43Z","timestamp":1772034103138,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"FOCA"},{"DOI":"10.13039\/501100010355","name":"Hellenic Society of Medical Oncology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010355","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ctrv.2014.09.004","type":"journal-article","created":{"date-parts":[[2014,10,5]],"date-time":"2014-10-05T20:03:09Z","timestamp":1412539389000},"page":"1129-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Small breast cancers: When and how to treat"],"prefix":"10.1016","volume":"40","author":[{"given":"K.","family":"Tryfonidis","sequence":"first","affiliation":[]},{"given":"D.","family":"Zardavas","sequence":"additional","affiliation":[]},{"given":"F.","family":"Cardoso","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.09.004_b0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jnci\/93.2.112","article-title":"Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.09.004_b0010","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1200\/JCO.1993.11.11.2090","article-title":"Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0\/T2N0M0 patients with long-term follow-up","volume":"11","author":"Rosen","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0015","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1634\/theoncologist.2010-0036","article-title":"Prognosis and outcome of small (\u2a7d1cm), node-negative breast cancer on the basis of hormonal and HER-2 status","volume":"15","author":"Amar","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2014.09.004_b0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.1989.7.9.1239","article-title":"Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18years","volume":"7","author":"Rosen","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1467-842X.2004.tb00435.x","article-title":"Female breast cancers are getting smaller, but socio-demographic differences remain","volume":"28","author":"Luke","year":"2004","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.ctrv.2014.09.004_b0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sj.bjc.6602075","article-title":"Decreased rates of advanced breast cancer due to mammography screening in The Netherlands","volume":"91","author":"Fracheboud","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0035","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10459","article-title":"Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975\u20131999","volume":"94","author":"Vacek","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0040","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/bjc.2011.144","article-title":"Explaining the difference in prognosis between screen-detected and symptomatic breast cancers","volume":"104","author":"Allgood","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0045","unstructured":"Surveillance, Epidemiology and End Results registry (SEER). http:\/\/www seer cancer gov 2013."},{"key":"10.1016\/j.ctrv.2014.09.004_b0050","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2013.53.1608","article-title":"Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study","volume":"32","author":"Vaz-Luis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0055","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00000421-198710000-00006","article-title":"Development and use of a natural history data base of breast cancer studies","volume":"10","author":"Moon","year":"1987","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0060","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1200\/JCO.1995.13.5.1144","article-title":"Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up","volume":"13","author":"Quiet","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0065","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.2004.09.070","article-title":"Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies","volume":"22","author":"Chia","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0070","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/annonc\/mdt532","article-title":"Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study","volume":"25","author":"Houvenaeghel","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0075","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/annonc\/mdh434","article-title":"Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies","volume":"15","author":"Colleoni","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0080","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1200\/JCO.2009.22.0962","article-title":"Clinical relevance of HER2 overexpression\/amplification in patients with small tumor size and node-negative breast cancer","volume":"27","author":"Curigliano","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0085","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1200\/JCO.2009.23.2025","article-title":"High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1cm or smaller","volume":"27","author":"Gonzalez-Angulo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0090","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1002\/cncr.26171","article-title":"Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer","volume":"117","author":"McArthur","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0095","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1200\/JCO.2010.29.7952","article-title":"Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas","volume":"28","author":"Rodrigues","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0100","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1200\/JCO.2013.52.0858","article-title":"Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive t1a and t1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system","volume":"32","author":"Fehrenbacher","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0105","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan CC, Holmes E, Spielmann M, et al. The prognosis of small HER2+ breast cancers: a meta-analysis of the randomized trastuzumab trials, ABSRACT S6-03, SABCS 2013.","DOI":"10.1158\/0008-5472.SABCS13-S6-03"},{"key":"10.1016\/j.ctrv.2014.09.004_b0115","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1994.12.5.888","article-title":"Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer","volume":"12","author":"Nixon","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","article-title":"Elevated breast cancer mortality in women younger than age 40years compared with older women is attributed to poorer survival in early-stage disease","volume":"208","author":"Gnerlich","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ctrv.2014.09.004_b0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/1471-2407-10-557","article-title":"Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1cm or less","volume":"10","author":"Kwon","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clbc.2011.05.002","article-title":"Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype","volume":"11","author":"Theriault","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10549-011-1465-7","article-title":"Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes","volume":"127","author":"Cancello","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2014.09.004_b0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2407-12-158","article-title":"Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study","volume":"12","author":"Gori","year":"2012","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2014.09.004_b0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.breast.2013.02.014","article-title":"Adjuvant chemotherapy in T1a\/bN0 HER2-positive or triple-negative breast cancers: application and outcomes","volume":"22","author":"Migdady","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2014.09.004_b0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM198902233200801","article-title":"A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0155","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1200\/JCO.1996.14.7.1982","volume":"14","author":"Fisher","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0160","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1200\/JCO.2005.02.8035","article-title":"Prognosis and management of patients with node-negative invasive breast carcinoma that is 1cm or smaller in size (stage 1; T1a, b N0M0): a review of the literature","volume":"24","author":"Hanrahan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0165","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2002.11.101","article-title":"Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less","volume":"20","author":"Fisher","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0170","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0175","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","article-title":"Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer","volume":"89","author":"Fisher","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.09.004_b0180","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0185","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"Van\u2019t Veer","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.09.004_b0190","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0195","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jnci\/djj329","article-title":"Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer","volume":"98","author":"Buyse","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.09.004_b0200","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1245\/s10434-009-0902-x","article-title":"Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature","volume":"17","author":"Mook","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0205","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0210","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0215","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0220","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0225","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Barry WT, Dang CT, et al. A phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2 positive breast cancer. In: 2013 San Antonio breast cancer symposium, Abstract S1-04.","DOI":"10.1158\/0008-5472.SABCS13-S1-04"},{"key":"10.1016\/j.ctrv.2014.09.004_b0230","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0235","unstructured":"National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. NCCN; 2013."},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2014.09.004_b0240","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Senkus","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0245","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/BD-2004-21105","article-title":"Chemotherapy for small (<1cm) breast cancers","volume":"21","author":"Soule","year":"2004","journal-title":"Breast Dis"},{"key":"10.1016\/j.ctrv.2014.09.004_b0250","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2007.14.3222","article-title":"Clinical application of the 70-gene profile: the MINDACT trial","volume":"26","author":"Cardoso","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0255","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMra0801289","article-title":"Gene-expression signatures in breast cancer","volume":"360","author":"Sotiriou","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0260","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1073\/pnas.0409462102","article-title":"Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival","volume":"102","author":"Chang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2014.09.004_b0265","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jnci\/djj052","article-title":"Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis","volume":"98","author":"Sotiriou","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.09.004_b0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(05)70933-8","article-title":"Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer","volume":"365","author":"Wang","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2014.09.004_b0275","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2007.15.1068","article-title":"Development of the 21-gene assay and its application in clinical practice and clinical trials","volume":"26","author":"Sparano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0280","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-07-4756","article-title":"Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes","volume":"14","author":"Desmedt","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.09.004_b0285","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr2124","article-title":"Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures","volume":"10","author":"Wirapati","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2014.09.004_b0290","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10549-010-0814-2","article-title":"The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer","volume":"120","author":"Knauer","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2014.09.004_b0295","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm1764","article-title":"Stromal gene expression predicts clinical outcome in breast cancer","volume":"14","author":"Finak","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2014.09.004_b0300","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/gb-2007-8-8-r157","article-title":"An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer","volume":"8","author":"Teschendorff","year":"2007","journal-title":"Genome Biol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0305","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0046-8177(95)90010-1","article-title":"Histological grading of breast carcinomas: a study of interobserver agreement","volume":"26","author":"Robbins","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0310","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/1097-0142(197908)44:2<671::AID-CNCR2820440238>3.0.CO;2-V","article-title":"Prognostic value of estrogen receptors in primary breast cancer","volume":"44","author":"Hahnel","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0315","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/1097-0142(19840601)53:11<2525::AID-CNCR2820531126>3.0.CO;2-8","article-title":"Estrogen receptors and long-term prognosis in breast cancer","volume":"53","author":"Aamdal","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/erm.09.69","article-title":"Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care","author":"Roukos","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ctrv.2014.09.004_b0325","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.09.004_b0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrc795","article-title":"Modelling the molecular circuitry of cancer","volume":"2","author":"Hahn","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0335","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/fon.13.57","article-title":"Personalized therapy for breast cancer: a dream or a reality?","volume":"9","author":"Zardavas","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0340","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrclinonc.2013.29","article-title":"Emerging targeted agents in metastatic breast cancer","volume":"10","author":"Zardavas","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00000658-198101000-00003","article-title":"Predictors of recurrence in stage I (T1N0M0) breast carcinoma","volume":"193","author":"Rosen","year":"1981","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2014.09.004_b0350","first-page":"151","article-title":"Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter","volume":"175","author":"Stierer","year":"1992","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.ctrv.2014.09.004_b0355","first-page":"271","article-title":"Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10mm or less detected clinically and by screening","volume":"160","author":"Arnesson","year":"1994","journal-title":"Eur J Surg"},{"key":"10.1016\/j.ctrv.2014.09.004_b0360","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/1097-0142(19951201)76:11<2266::AID-CNCR2820761114>3.0.CO;2-T","article-title":"Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a, b N0M0)","volume":"76","author":"Leitner","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.09.004_b0365","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10434-999-0591-5","article-title":"Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma","volume":"6","author":"Mann","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2014.09.004_b0370","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00000658-200206000-00014","article-title":"Can we select which patients with small breast cancers should receive adjuvant chemotherapy?","volume":"235","author":"Wood","year":"2002","journal-title":"Ann Surg"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T11:49:25Z","timestamp":1598356165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214001649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0305737214001649"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.09.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small breast cancers: When and how to treat","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}